| Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal (NCT05530759) | Mayo Clinic | 2022-06-29 |
| Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) (NCT05371132) | City of Hope Medical Center | 2022-06-20 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors (NCT05010096) | M.D. Anderson Cancer Center | 2022-03-22 |
| SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial (NCT05222620) | Mayo Clinic | 2022-03-14 |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (NCT04840589) | National Cancer Institute (NCI) | 2022-02-02 |
| Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis (NCT05059678) | M.D. Anderson Cancer Center | 2021-11-30 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Perception of Cure Among Patients With Metastatic Cancer (NCT04820894) | City of Hope Medical Center | 2021-10-30 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497) | National Cancer Institute (NCI) | 2021-10-20 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses (NCT04960787) | SWOG Cancer Research Network | 2021-10-12 |
| Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression (NCT04957615) | M.D. Anderson Cancer Center | 2021-09-21 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery (NCT04588246) | NRG Oncology | 2021-08-05 |
| Radiosurgery Before Surgery for the Treatment of Brain Metastases (NCT04895592) | Emory University | 2021-07-20 |
| Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (NCT04639245) | Fred Hutchinson Cancer Center | 2021-07-19 |
| Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers (NCT04090619) | M.D. Anderson Cancer Center | 2021-06-22 |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer (NCT04585958) | National Cancer Institute (NCI) | 2021-05-21 |
| Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit (NCT05091632) | M.D. Anderson Cancer Center | 2021-05-04 |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors (NCT04879121) | M.D. Anderson Cancer Center | 2021-04-30 |
| Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer (NCT05058339) | M.D. Anderson Cancer Center | 2021-04-27 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (NCT04785287) | M.D. Anderson Cancer Center | 2021-03-29 |
| Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor (NCT04800627) | M.D. Anderson Cancer Center | 2021-03-29 |
| Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial (NCT04693377) | M.D. Anderson Cancer Center | 2021-03-16 |
| Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers (NCT04062552) | University of Rochester NCORP Research Base | 2021-03-09 |
| SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (NCT04729725) | M.D. Anderson Cancer Center | 2021-02-09 |
| Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer (NCT04697524) | University of California, San Francisco | 2021-01-26 |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (NCT04789668) | M.D. Anderson Cancer Center | 2021-01-15 |
| A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma (NCT05101356) | University of California, Davis | 2021-01-13 |
| PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning (NCT04889144) | Fred Hutchinson Cancer Center | 2021-01-01 |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (NCT04693468) | M.D. Anderson Cancer Center | 2020-12-01 |
| An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors (NCT04539574) | M.D. Anderson Cancer Center | 2020-09-04 |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628) | National Cancer Institute (NCI) | 2020-09-01 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers (NCT04388852) | M.D. Anderson Cancer Center | 2020-08-20 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (NCT04317105) | National Cancer Institute (NCI) | 2020-07-17 |
| Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713) | National Cancer Institute (NCI) | 2020-06-30 |
| Testing the Safety of CB-5339 in Patients With Cancer (NCT04372641) | National Cancer Institute (NCI) | 2020-06-18 |
| NCI COVID-19 in Cancer Patients, NCCAPS Study (NCT04387656) | National Cancer Institute (NCI) | 2020-06-05 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194) | National Cancer Institute (NCI) | 2020-04-07 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912) | M.D. Anderson Cancer Center | 2020-03-17 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744) | Mayo Clinic | 2020-02-13 |
| Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations (NCT04233567) | Sameek Roychowdhury | 2020-01-16 |
| Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCT03842228) | National Cancer Institute (NCI) | 2019-11-21 |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases (NCT03994796) | Alliance for Clinical Trials in Oncology | 2019-10-17 |
| BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (NCT04021043) | M.D. Anderson Cancer Center | 2019-08-19 |
| Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (NCT03907475) | National Cancer Institute (NCI) | 2019-07-16 |
| Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer (NCT03927885) | M.D. Anderson Cancer Center | 2019-03-30 |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers (NCT03868423) | Sameek Roychowdhury | 2019-03-20 |
| SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies (NCT03831295) | Ronald Levy | 2019-03-13 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (NCT03284385) | National Cancer Institute (NCI) | 2019-01-29 |
| ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors (NCT03725436) | M.D. Anderson Cancer Center | 2019-01-24 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer (NCT03579446) | M.D. Anderson Cancer Center | 2018-11-29 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054) | Rahul Aggarwal | 2018-08-20 |
| Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases (NCT05054998) | M.D. Anderson Cancer Center | 2018-08-03 |
| Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors (NCT03525925) | Ohio State University Comprehensive Cancer Center | 2018-07-18 |
| Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer (NCT03583255) | M.D. Anderson Cancer Center | 2018-06-29 |
| Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (NCT03030378) | National Cancer Institute (NCI) | 2018-05-30 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (NCT03326258) | National Cancer Institute (NCI) | 2018-04-20 |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors (NCT03366103) | National Cancer Institute (NCI) | 2018-03-20 |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction (NCT03217253) | National Cancer Institute (NCI) | 2018-03-16 |
| Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers (NCT03017833) | M.D. Anderson Cancer Center | 2018-03-12 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (NCT03428802) | Rutgers, The State University of New Jersey | 2018-03-08 |
| Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors (NCT03237390) | Mayo Clinic | 2018-01-04 |
| Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients (NCT06015932) | Mayo Clinic | 2017-12-20 |
| IACS-010759 in Advanced Cancers (NCT03291938) | M.D. Anderson Cancer Center | 2017-11-13 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCT03065387) | M.D. Anderson Cancer Center | 2017-10-31 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (NCT03217747) | M.D. Anderson Cancer Center | 2017-08-02 |
| Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy (NCT03080883) | Academic and Community Cancer Research United | 2017-07-14 |
| Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer (NCT02862275) | National Cancer Institute (NCI) | 2017-05-24 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery (NCT03184038) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-02-21 |
| Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors (NCT03035409) | M.D. Anderson Cancer Center | 2017-02-08 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (NCT02721732) | M.D. Anderson Cancer Center | 2016-08-15 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931) | National Cancer Institute (NCI) | 2016-07-22 |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer (NCT02321501) | M.D. Anderson Cancer Center | 2016-06-22 |
| Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy (NCT02710253) | M.D. Anderson Cancer Center | 2016-05-25 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861) | National Cancer Institute (NCI) | 2015-10-21 |
| Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer (NCT02317874) | National Cancer Institute (NCI) | 2015-09-08 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types (NCT06075524) | Mayo Clinic | 2015-06-15 |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer (NCT02474160) | National Cancer Institute LAO | 2015-05-19 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases (NCT02387905) | M.D. Anderson Cancer Center | 2015-03-09 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors (NCT02143401) | National Cancer Institute (NCI) | 2015-01-30 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740) | National Cancer Institute (NCI) | 2014-03-26 |
| Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (NCT02070549) | National Cancer Institute (NCI) | 2014-03-10 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus (NCT01822522) | National Cancer Institute (NCI) | 2013-06-21 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139) | M.D. Anderson Cancer Center | 2013-02-19 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |